

Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study)

I Nicol Ferrier,^{1,2} Ian M Anderson,³ Jane Barnes,⁴ Peter Gallagher,¹ Heinz CR Grunze,^{1,2} Peter M Haddad,³ Allan O House,⁵ Tom Hughes,⁶ Adrian J Lloyd,^{1,2} Chrysovalanto Mamasoula,⁴ Elaine McColl,⁴ Simon Pearce,⁷ Najma Siddiqi,⁸ Baxi Sinha,⁹ Chris Speed,⁴ Nick Steen,⁴ June Wainwright,⁹ Stuart Watson,^{1,2} Fiona H Winter,⁹ R Hamish McAllister-Williams^{1,2*} and the ADD Study Team

¹Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

²Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK

³Greater Manchester West Mental Health NHS Foundation Trust and Neuroscience and Psychiatry Unit, Manchester University, Manchester, UK

⁴Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK

⁵Institute of Health Sciences, University of Leeds, Leeds, UK

⁶Leeds and York Partnership NHS Foundation Trust, Leeds, UK

⁷Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

⁸Bradford District NHS Care Trust, Saltaire, West Yorkshire, UK

⁹Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington, County Durham, UK

*Corresponding author

Declared competing interests of authors: Dr McA-W reports grants from the Northumberland, Tyne and Wear Comprehensive Local Research Network, and Northumberland, Tyne and Wear NHS Foundation Trust (Research Capacity Funding) during the conduct of the study. INF reports grants from the Northumberland, Tyne and Wear NHS Foundation Trust (Research Capacity Funding) during the conduct of the study. EMcC is a member of the National Institute for Health Research Journal Editorial Group. HG reports personal fees from Bristol-Myers Squibb (BMS), Desitin, Lundbeck, Hoffmann-La Roche, Servier, Sanofi-aventis, and Richter Gedeon, outside the submitted work. IA reports personal fees from Lundbeck and Alberta Psychiatric Association, and royalties from Springer, outside the submitted work. He also reports fees paid to his institution from Servier, Alkermes, AstraZeneca and Medicine Publishing (Elsevier) during the conduct of the study. PMH reports personal fees and non-financial support from Janssen, Eli Lilly and Company, Otsuka and Servier, and personal fees from Sunovion, Lundbeck, BMS and AstraZeneca, outside the submitted work. SW reports grants from the Efficacy and Mechanism Evaluation board of the Medical Research Council during the conduct of the study.

Published June 2015

DOI: 10.3310/eme02040

Plain English summary

The ADD Study

Efficacy and Mechanism Evaluation 2015; Vol. 2: No. 4

DOI: 10.3310/eme02040

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain English summary

Depression is common and can have a terrible impact on patients and their families. Guidelines recommend talking therapies for patients with milder depression and adding antidepressants for moderate and severe depression. However, antidepressants work in only about 70% of sufferers. Why this happens is not known. One possibility is that increases in the stress hormone cortisol may reduce the effectiveness of antidepressants. Cortisol rises when people are stressed and may stay high in depression. Raised cortisol reduces the effect of antidepressants on the chemicals in the brain, which are thought to be important in how they work. Small studies have suggested that reducing the level of cortisol produces better outcomes for depression. We have tested the drug metyrapone, which blocks the production of cortisol, in a group of 165 people who remained depressed after previous treatment with at least two antidepressants. Metyrapone was given for 3 weeks. We investigated whether or not it led to benefits over the next 6 months compared with a group of similar people who received dummy tablets. Both groups of depressed people improved but there was no difference between them. There was also no difference in anxiety scores or quality of life with metyrapone treatment. Changes in memory, processing emotions and brain function were found in the depressed patients but no effects of metyrapone were found. It appears that this particular drug does not produce benefits for such patients. Further research is needed to find a treatment that reduces the effects of cortisol and improves the outcome for depression.

Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Efficacy and Mechanism Evaluation* journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/eme>

This report

The research reported in this issue of the journal was funded by the EME programme as project number 08/43/39. The contractual start date was in May 2010. The final report began editorial review in June 2014 and was accepted for publication in January 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2015. This work was produced by Ferrier *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Efficacy and Mechanism Evaluation Editor-in-Chief

Professor Raj Thakker May Professor of Medicine, Nuffield Department of Medicine, University of Oxford, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson Director of NETSCC, HTA, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk